Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorder
Open Access
Abstract
BACKGROUND: Although the literature reports a low incidence of Burkitt lymphoma (BL) as a post‐transplant lymphoproliferative disorder (PTLD), this entity appears to be different from other monomorphic PTLDs (M‐PTLDs), both in its aggressive clinical presentation and its distinct pathologic profile.METHODS: Patients with BL, diagnosed in the post‐transplant setting, (patients aged ≤18 years) were retrieved from the pathology archives at Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center from 1982 to 2010. Clinical outcomes were obtained along with pathologic review.RESULTS: Twelve patients with pediatric BL in the post‐transplant setting (9 boys, 3 girls) were retrieved. The patients displayed a monomorphic population of small to intermediate‐sized, noncleaved, lymphoid elements with a “starry‐sky” pattern. The immunophenotype for patients available to the study was CD20+ (n = 9/10), CD10+ (n = 8/8), bcl‐6+ (n = 11/11), with a near 100% Ki‐67/MIB‐1 proliferation index (n = 7/7), and negative for TdT (n = 7/7). Most pretransplant Epstein‐Barr virus titers were negative (n = 8/10), with post‐transplant titers positive in all tested patients (n = 11), and with positive Epstein‐Barr–encoded RNA in situ hybridization in most cases (n = 9/11). The median time from transplantation to diagnosis was 52 months (range, 6‐107 months). Nine patients were currently alive after immediate antineoplastic chemotherapy, with median disease‐free time of 93 months from diagnosis (range, 2‐199 months).CONCLUSIONS: BL‐PTLD had a higher Epstein‐Barr virus incidence compared with sporadic and immunodeficiency‐associated BL and represented a distinct monomorphic PTLD. Although some M‐PTLDs can be managed less aggressively with decreased immunosuppression alone, immediate lymphoma‐specific chemotherapy was associated with a favorable outcome and was strongly recommended. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Port-Site Metastasis after Laparoscopic Biopsy of a Posttransplant Burkitt Lymphoma in a ChildEuropean Journal of Pediatric Surgery, 2008
- MYC translocation‐negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulationThe Journal of Pathology, 2008
- Laboratory Assays for Epstein-Barr Virus-Related DiseaseThe Journal of Molecular Diagnostics, 2008
- Genetic and phenotypic analysis of B‐cell post‐transplant lymphoproliferative disorders provides insights into disease biologyHematological Oncology, 2008
- Chronic High Epstein-Barr Viral Load State and Risk for Late-Onset Posttransplant Lymphoproliferative Disease/Lymphoma in ChildrenAmerican Journal of Transplantation, 2008
- Clinicopathologic Findings in High-Grade B-Cell Lymphomas With Typical Burkitt Morphologic Features but Lacking theMYCTranslocationAmerican Journal of Clinical Pathology, 2007
- EBNA2 Interferes with the Germinal Center Phenotype by Downregulating BCL6 and TCL1 in Non-Hodgkin's Lymphoma CellsJournal of Virology, 2007
- Development of a Biologically Distinct EBV-Related Lymphoproliferative Disorder Following Autologous Bone Marrow Transplantation for an EBV-Negative Post-Renal Allograft Burkitt's LymphomaLeukemia & Lymphoma, 2000
- EPSTEIN-BARR VIRUS ASSOCIATED BURKITT LYMPHOMA IN A HEART TRANSPLANT RECIPIENT1Transplantation, 1996
- Description of an In Situ Hybridization Methodology for Detection of Epstein-Barr Virus RNA in Paraffin-Embedded Tissues, with a Survey of Normal and Neoplastic TissuesDiagnostic Molecular Pathology, 1992